OA08.05LB Development of a novel VRC01-class germline targeting immunogen derived from anti-idiotypic antibodiesOral Abstract SessionNovel vaccine and other prevention approaches
OA09.01 BCG.HTI2auxo.int priming vaccination enhances the HIV-1 specific T cell immune responses elicited by MVA.HTIOral Abstract SessionNovel vaccine and other prevention approaches
OA09.02 Anti-Env antibody-independent protection of repeated intrarectal low-dose SIVmac239 challenges in rhesus macaques by vaccination inducing Gag/Vif-specific CD8+ T but not CD4+ T cellsOral Abstract SessionMucosal immunity
OA09.03 Impact of HLA-II associated HIV-1 adaptations on vaccine-induced CD4 T-cell immune responsesOral Abstract SessionCellular immunity
OA09.04 Applying insights from HIV to guide the development of a T-cell vaccine for SARS-CoV-2Oral Abstract SessionCOVID research: Applying lessons from HIV prevention to SARS CoV-2
OA09.05LB Spontaneous in vivo control of HIV replication is underpinned by the cross-clade antiviral potency of HIV-specific CD8 T cellsOral Abstract SessionCellular immunity
OA10.01 Planning for success: generating an early roadmap with global stakeholders for increasing access and uptake of new biomedical prevention products in resource-limited settings: The *Biomedical Prevention Implementation C*ollaborative (BioPIC)Oral Abstract SessionPolicy and advocacy
OA10.02 Pathways to global access for novel HIV prevention technologiesOral Abstract SessionPolicy and advocacy
OA10.03 Advocates' perspectives on an efficacy trial of F/TAF as PrEP for womenOral Abstract SessionCommunity engagement in prevention research
OA10.04 Amplifying youth voices in HIV prevention: lessons learned from a community-based adolescent health project in Durham, NCOral Abstract SessionCommunity engagement in prevention research
seek-warrow-warrow-eseek-e41 - 50 of 444 items